Breakthroughs in Stem Cell Research
Optimism continues to grow about the use of stem cells in regenerative medicine highlighted by hundreds of successful clinical trials.
Large-Dose Albumin Supplementation Does Not Reduce Mortality or Need for Critical Care Interventions: Retrospective Review
Investigators conducted a retrospective review of 38 cases treated at Taipei Veterans General Hospital between January 2007 and December 2018 to determine whether more aggressive albumin supplementation can benefit major burn patients with persistent hypoalbuminemia.
Study Finds Safe Treatment for Children with Severe Hemophilia A with Inhibitors
Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.
FDA Expands Indication for Octapharma’s WILATE to Hemophilia A
The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.
Medicare Will Now Cover Acupuncture for Chronic Low Back Pain
The Centers for Medicare and Medicaid Services (CMS) finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.
Plasma-Derived ApoA-1
Findings suggest CSL112 can boost cholesterol efflux capacity in patients with impaired endogenous HDL function. Encouragingly, several studies have documented its ability to reduce atherosclerotic plaque volume.
Nutrigenomics: How Genes and Nutrition Interact
Using nutrition to benefit health through the care and feeding of genes, though still in its infancy, is an exciting field of study seeing exponential growth.
SCIG with Recombinant Human Hyaluronidase Is Safe and Preferred vs IVIG by Some Multifocal Motor Neuropathy Patients
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).
Excellent Response to Therapeutic Plasma Exchange in Myasthenia Gravis Patients with or Without Autoantibodies
A study out of the University of Texas Southwestern Medical Center found a 96 percent response rate to treatment with therapeutic plasma exchange (PLEX) in a series of 58 consecutive myasthenia gravis (MG) patients, with no significant difference in response between those with or without autoantibodies.
Novo Nordisk’s Esperoct Approved to Treat Individuals with Hemophilia A
FDA approved Esperoct (antihemophilic factor[recombinant], glycopegylatedexei), an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A.
